Evidence map›Paper›PMID 33579345›Full record

ArticleTrials2021

Comparative study of the effect of neuromuscular electrical stimulation and oral administration of branched-chain amino acid on preventing sarcopenia in patients after living-donor liver transplantation: study protocol for an open-label randomized controlled trial.

Masafumi Haraguchi, Kunihiro Ichinose, Hisamitsu Miyaaki, Masatoshi Hanada, Masanori Fukushima, Ryu Sasaki, Satoshi Miuma, Takanobu Hara, Tota Kugiyama, Akihiko Soyama and 7 more

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Masafumi Haraguchi *Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.
Kunihiro Ichinose *Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Nagasaki, Japan.
Hisamitsu MiyaakiDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan. miyaaki-hi@nagasaki-u.ac.jp.ORCID http://orcid.org/0000-0002-8564-0490
Masatoshi HanadaCardiorespiratory Division, Department of Rehabilitation Medicine, Nagasaki University Hospital, Nagasaki City, Nagasaki, 852-8501, Japan.
Masanori FukushimaDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.
Ryu SasakiDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.
Satoshi MiumaDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.
Takanobu HaraDepartment of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Nagasaki, 852-8501, Japan.
Tota KugiyamaDepartment of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Nagasaki, 852-8501, Japan.
Akihiko SoyamaDepartment of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Nagasaki, 852-8501, Japan.
Masaaki HidakaDepartment of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Nagasaki, 852-8501, Japan.
Ayumi TsujiDepartment of Nurse, Nagasaki University Hospital, Nagasaki City, Nagasaki, 852-8501, Japan.
Rintaro YanoDivision of Intensive Care, Nagasaki University Hospital, Nagasaki City, Nagasaki, 852-8501, Japan.
Motohiro SekinoDivision of Intensive Care, Nagasaki University Hospital, Nagasaki City, Nagasaki, 852-8501, Japan.
Hideaki TakahataCardiorespiratory Division, Department of Rehabilitation Medicine, Nagasaki University Hospital, Nagasaki City, Nagasaki, 852-8501, Japan.
Susumu EguchiDepartment of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Nagasaki, 852-8501, Japan.
Kazuhiko NakaoDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.
Nagasaki University · JPNagasaki University Hospital · JP

Funding

Japan Society for the Promotion of Science 20K19311
6 · The paper itself

Abstract

backgroundLiver cirrhosis is the irreversible fibrosis of the liver and causes refractory ascites and hepatic encephalopathy, which might not respond to treatment. Living donor liver transplantation (LDLT) is an effective treatment for patients with cirrhosis. However, post-LDLT patients are prone to muscle atrophy and sarcopenia. Therefore, physiotherapy of post-LDLT patients is essential for preventing the progression of sarcopenia. Recently, rehabilitation using neuromuscular electrical stimulation (NMES) has been reported to be useful for preventing the progression of sarcopenia. Similarly, nutrition therapy is essential for post-LDLT patients because these patients frequently experience malnutrition. However, the effects of combined NMES and nutrition therapy on post-LDLT patients remain unknown. METHODS/

designThis open-label, randomized, parallel-group study will compare the effects of combined therapy with NMES and branched-chain amino acids (BCAA) with those of NMES alone in patients with decompensated cirrhosis after LDLT. After LDLT, 50 patients with decompensated cirrhosis will be randomly assigned to receive NMES with BCAA or NMES without BCAA. The duration of the intervention will be 3 months. To analyze the change in skeletal muscle mass, InBody 770 body composition and body water analysis and ultrasonography will be performed before LDLT and 4 weeks and 12 weeks post-LDLT. The primary endpoint is changes in the skeletal muscle mass from baseline to 3 months. Important secondary endpoints are the changes in the skeletal muscle mass from baseline to 1 month and changes in the quadriceps strength from baseline to 1 month. DISCUSSION: The results of this study are expected to provide evidence regarding the effect of NMES combined with BCAA therapy on the skeletal muscle of post-LDLT patients.

trial registrationJapan Registry of Clinical Research jRCTs071190051 . Registered on February 26, 2020.

Indexed as

Electric Stimulation TherapyLiver TransplantationSarcopeniaAdministration, OralAmino Acids, Branched-ChainElectric StimulationHumansJapanLiving DonorsMuscle, SkeletalRandomized Controlled Trials as TopicAmino Acids, Branched-ChainBranched-chain amino acidsDecompensated cirrhosisLiving donor liver transplantationNeuromuscular electrical stimulationSarcopenia

Identifiers

PMID33579345
PMCPMC7881684
OpenAlexW3127680515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.